• JNJ-26481585 (Quisinostat): Targeting TRIM21 for Tumor Sensi

  2026-05-17

  This in-depth review explores JNJ-26481585 (Quisinostat) as an advanced HDAC inhibitor for cancer research, emphasizing its unique role in modulating TRIM21 and overcoming drug resistance. Discover mechanistic insights and practical assay guidance not found in standard protocol articles.

• TH287 MTH1 Inhibitor Enhances Radiosensitivity in CRPC Cells

  2026-05-16

  This study demonstrates that the MTH1 inhibitor TH287 significantly increases the radiosensitivity of castration-resistant prostate cancer (CRPC) cells by amplifying DNA damage and apoptosis when combined with ionizing radiation. The findings provide mechanistic insight into radiosensitization timing and offer a protocol framework for future translational research.

• Triacetin Modulates HDACs and miRNAs to Induce Apoptosis in

  2026-05-15

  This study demonstrates that Triacetin (glyceryl triacetate) induces apoptosis in glioblastoma (GBM) cells by modulating tumor-suppressor microRNAs and reducing class I/II HDAC gene expression. The findings provide mechanistic insight into Triacetin’s epigenetic and metabolic effects, supporting its potential as a research tool for exploring GBM therapeutic strategies.

• Dextromethorphan Hydrobromide: Optimizing NMDA Antagonist Wo

  2026-05-15

  Dextromethorphan hydrobromide stands out as a high-purity NMDA receptor antagonist for precise neuroprotection and excitotoxicity research. This guide details advanced experimental setups, protocol fine-tuning, and troubleshooting for reproducible results with APExBIO’s reagent.

• Ibrexafungerp (MK 3118): Forging New Paths in Antifungal Res

  2026-05-14

  This article provides translational researchers with a strategic, mechanistic, and evidence-based perspective on Ibrexafungerp (MK 3118), the first-in-class oral triterpenoid antifungal. It examines the biological rationale for targeting 1,3-β-D-glucan synthase, reviews pivotal in vitro and in vivo data—including efficacy against multidrug-resistant Candida auris—and distills actionable protocol guidance. By benchmarking Ibrexafungerp's clinical relevance, competitive advantages, and future directions, this piece delivers unique strategic value, differentiating itself from standard product summaries and deepening the translational bridge for antifungal innovation.

• Digestion and Metabolic Fate of Triacetin: New Insights from

  2026-05-14

  This study provides the first detailed investigation of how triacetin, a short-chain triglyceride, is digested and absorbed in vivo. The findings reveal complete hydrolysis in the upper GI tract and demonstrate triacetin's dual roles as a metabolic substrate and regulator of hepatic gene expression, offering new avenues for metabolic research.

• Lamotrigine in Applied Neuroscience: Protocols and Troublesh

  2026-05-13

  Lamotrigine, a high-purity sodium channel blocker and 5-HT inhibitor, empowers both CNS and cardiac research with reproducible, translational workflows. This guide delivers protocol-driven insights, troubleshooting strategies, and comparative advantages for bench scientists leveraging APExBIO's Lamotrigine in advanced sodium channel and serotonin assays.

• 2-Hydroxypropyl-β-cyclodextrin: Solubility Protocol and QC G

  2026-05-13

  2-Hydroxypropyl-β-cyclodextrin addresses solubility limitations for poorly water-soluble, hydrophobic compounds—especially those containing aromatic or phenyl groups—by forming inclusion complexes to enhance aqueous solubility. It is recommended strictly for use as a drug formulation excipient or in pharmaceutical solubility enhancement workflows. Applications outside these domains are not supported by current product documentation.

• 2-D08 (2’,3’,4’-trihydroxyflavone) in Precision Sumoylation

  2026-05-12

  2-D08 (2’,3’,4’-trihydroxyflavone) offers researchers a uniquely selective approach to inhibiting protein sumoylation, empowering the study of posttranslational modifications in cancer and mitochondrial quality control. Its mechanism-focused workflow compatibility and robust performance in cellular models set a new benchmark for dissecting dynamic regulatory pathways.

• Bazedoxifene Inhibits IL-6/GP130: Mechanisms and Cancer Rese

  2026-05-12

  Shi et al. (2024) review the emerging role of bazedoxifene as a novel inhibitor of the IL-6/GP130 signaling axis in cancer. By elucidating the mechanistic and experimental evidence for bazedoxifene's repositioning as an anticancer agent, this work highlights opportunities to target cytokine-driven tumor survival and resistance.

• Calcitriol: Mechanisms, Benchmarks, and Immune Modulation In

  2026-05-11

  Calcitriol, the active metabolite of vitamin D3, regulates bone and immune homeostasis through vitamin D receptor signaling and cytokine modulation. This article details its precise mechanisms, solubility, and benchmarks for research applications. Key misconceptions and practical parameters are clarified for robust experimental design.

• Trichostatin A in Epigenetic Regulation and Cancer Workflows

  2026-05-11

  Trichostatin A (TSA) stands out as a gold-standard HDAC inhibitor for dissecting epigenetic regulation in cancer, tissue regeneration, and cellular differentiation. This article delivers a practical guide to TSA workflows, troubleshooting, and novel insights, bridging bench protocols with advanced research on blastema formation and cancer inhibition.

• D-N-Acetylgalactosamine: Technical Guidance for Brain Glycop

  2026-05-10

  D-N-Acetylgalactosamine is a high-purity, water-soluble glycoprotein constituent designed for researchers investigating glycosylation pathways and brain heteropolysaccharides. It is ideal for workflows requiring robust aqueous solubility and precision in glycoprotein analysis, but should not be used in protocols demanding ethanol solubility or long-term solution storage.

• mCherry mRNA: Applied Workflows for Robust Fluorescent Expre

  2026-05-09

  EZ Cap™ mCherry mRNA (5mCTP, ψUTP) from APExBIO unlocks next-level fluorescent protein expression with minimized immune activation, elevating both imaging fidelity and assay reproducibility. Drawing on novel nanoparticle encapsulation research, this guide details advanced experimental protocols, comparative advantages, and practical troubleshooting to maximize your reporter gene workflows.

• Targeting FOXO3 Suppresses Tumor Metabolism in Hepatocellula

  2026-05-09

  This study establishes FOXO3 as a central regulator of metabolic reprogramming in hepatocellular carcinoma (HCC) by demonstrating its dual inhibition of glycolysis and glutaminolysis via direct transcriptional repression of YAP. The findings highlight the FOXO3/YAP axis as a promising, metabolically-focused therapeutic target with implications for the development of combinatorial strategies in HCC treatment.

453 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page